292 related articles for article (PubMed ID: 32918610)
1. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
[TBL] [Abstract][Full Text] [Related]
2. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Taichman LS; Van Poznak CH; Inglehart MR
Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
[TBL] [Abstract][Full Text] [Related]
3. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
Borreani C; Alfieri S; Infante G; Miceli R; Mariani P; Bosisio M; Vernieri C; Bianchi GV; Capri G
Oncology; 2021; 99(2):84-95. PubMed ID: 32992318
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
[TBL] [Abstract][Full Text] [Related]
5. Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
de Paulo TRS; Winters-Stone KM; Viezel J; Rossi FE; Aro BL; Trindade ACAC; Codogno JS; Freitas Junior IF
Disabil Rehabil; 2019 Sep; 41(18):2175-2182. PubMed ID: 29644889
[No Abstract] [Full Text] [Related]
6. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
7. A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
Caperchione CM; Sabiston CM; Stolp S; Bottorff JL; Campbell KL; Eves ND; Ellard SL; Gotay C; Sharp P; Pullen T; Fitzpatrick KM
BMC Cancer; 2019 Mar; 19(1):272. PubMed ID: 30917793
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
[TBL] [Abstract][Full Text] [Related]
9. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
11. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors.
Jung AY; Behrens S; Schmidt M; Thoene K; Obi N; Hüsing A; Benner A; Steindorf K; Chang-Claude J
Breast Cancer Res; 2019 Nov; 21(1):117. PubMed ID: 31694687
[TBL] [Abstract][Full Text] [Related]
12. Relationship between physical activity practice and metabolic profile of postmenopausal women under treatment with aromatase inhibitors for breast cancer.
de Paulo TRS; Viezel J; Aro BL; Seidinger SC; Trindade ACAC; Christofaro DGD; Freitas IF
Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():33-37. PubMed ID: 28700959
[TBL] [Abstract][Full Text] [Related]
13. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
15. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
17. Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
Saito T; Ono R; Kono S; Asano M; Fukuta A; Tanaka Y; Takao S; Sakai Y
Breast Cancer Res Treat; 2020 Jul; 182(1):187-193. PubMed ID: 32399742
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.
Carlson RW; Hudis CA; Pritchard KI; ; ;
J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
20. Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors.
Nyrop KA; Callahan LF; Cleveland RJ; Arbeeva LL; Hackney BS; Muss HB
Oncologist; 2017 Oct; 22(10):1238-1249. PubMed ID: 28698390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
